食管鳞癌根治术后淋巴结复发的挽救治疗
本研究回顾性分析83例食管鳞癌根治术后区域淋巴结复发患者,评估挽救性放疗±化疗的疗效与预后因素。全组均接受放疗,中位剂量60Gy,41例单纯放疗、42例联合化疗。中位总生存18个月,3年生存率40.1%;多因素分析显示年龄与预后显著相关(p=0.034),3级毒性发生率18%,无治疗相关死亡。
要点
- 挽救性放疗±化疗对食管鳞癌术后淋巴结复发有效且可行。
- 全组中位OS 18个月,3年OS率40.1%,5年OS率35.1%。
- 单纯放疗与同步放化疗3年生存率无显著差异(p=0.570)。
核心结论
- 挽救性放疗±化疗是食管鳞癌根治术后淋巴结复发的有效且可行的治疗选择。
研究设计与样本
- 回顾性分析83例食管鳞癌根治术后区域淋巴结复发患者,均接受放疗,其中74例VMAT、9例3DCRT,剂量范围50.4-66.2Gy(中位60Gy)。
- 41例接受单纯放疗,42例接受放疗联合化疗,同步化疗以铂类或氟尿嘧啶单药为主,仅4例接受FP或TP方案。
主要发现
- 中位随访24个月(范围9-75个月),中位OS为18个月(范围5-75个月)。
- 1年、2年、3年、5年OS率分别为83.0%、57.1%、40.1%、35.1%。
- 单纯放疗组与同步放化疗组3年生存率分别为47.5%和41.9%(p=0.570),客观缓解率(CR+PR)分别为73.2%和91.4%。
- 多因素分析显示年龄与OS显著相关(年轻患者更差,p=0.034)。
- 常见毒性为食管炎、中性粒细胞减少和贫血,18%患者出现3级毒性,无治疗相关死亡。
临床怎么用
- 对于食管鳞癌根治术后区域淋巴结复发患者,可考虑采用挽救性放疗±化疗。
- 放疗剂量范围50.4-66.2Gy(中位60Gy)可供临床参考。
- 同步化疗可选铂类或氟尿嘧啶单药方案。
局限性
- 本研究为单中心回顾性分析,样本量83例,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. METHODS: The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4-66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). RESULTS: The median follow-up time was 24 (range, 9-75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5-75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. CONCLUSIONS: These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
引用
- Chen J, Yin W, Yao H, et al. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. Radiat Oncol. 2019. PMID: 31533757. doi:10.1186/s13014-019-1377-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。